Abstract
In vitro screening of 307 drugs with various clinical indications (cardiotropic, neurotropic, antibacterial, etc.) has revealed 6 compounds which displayed remarkable antiretroviral activity. Three of these drugs had a tendency to have undesirable side effects and were thus excluded from further consideration. Remaining three, i.e., Xantinol Nicotinate, Tardiferon, and Trental may become valid candidates for inclusion into antiviral regimens such as HAART. In vitro tests have shown that xantinol and trental display synergistic effect with azidothymidine, inhibit the replication AZT-resistant strains of HIV, and have no competing undesirable activities. These compounds should be evaluated in safety studies to determine optimal doses for patients with HIV. If these studies confirm in vitro results these compounds may become valid candidates as safe and affordable means to be added into the arsenal of antiretroviral drugs.
Keywords: Novel Inhibitors, HIV, Clinical Indications, antiretroviral activity, Xantinol Nicotinate, HAART
Current Pharmaceutical Design
Title: Novel Inhibitors of HIV Discovered Among Existing Classes of Pharmaceutical Compounds Indicated for Unrelated Clinical Indications
Volume: 15 Issue: 11
Author(s): I. I. Kucherov, P. G. Rytik, I. A. Podol'skaya, L. O. Mistryukova and M. O. Korjev
Affiliation:
Keywords: Novel Inhibitors, HIV, Clinical Indications, antiretroviral activity, Xantinol Nicotinate, HAART
Abstract: In vitro screening of 307 drugs with various clinical indications (cardiotropic, neurotropic, antibacterial, etc.) has revealed 6 compounds which displayed remarkable antiretroviral activity. Three of these drugs had a tendency to have undesirable side effects and were thus excluded from further consideration. Remaining three, i.e., Xantinol Nicotinate, Tardiferon, and Trental may become valid candidates for inclusion into antiviral regimens such as HAART. In vitro tests have shown that xantinol and trental display synergistic effect with azidothymidine, inhibit the replication AZT-resistant strains of HIV, and have no competing undesirable activities. These compounds should be evaluated in safety studies to determine optimal doses for patients with HIV. If these studies confirm in vitro results these compounds may become valid candidates as safe and affordable means to be added into the arsenal of antiretroviral drugs.
Export Options
About this article
Cite this article as:
Kucherov I. I., Rytik G. P., Podol'skaya A. I., Mistryukova O. L. and Korjev O. M., Novel Inhibitors of HIV Discovered Among Existing Classes of Pharmaceutical Compounds Indicated for Unrelated Clinical Indications, Current Pharmaceutical Design 2009; 15 (11) . https://dx.doi.org/10.2174/138161209787846856
DOI https://dx.doi.org/10.2174/138161209787846856 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Renin-Angiotensin-Aldosterone System in Metabolic Syndrome and Obesity-related Hypertension
Current Hypertension Reviews Endothelial Dysfunction, Impaired Endogenous Platelet Inhibition and Platelet Activation in Diabetes and Atherosclerosis
Current Vascular Pharmacology Implications of Pharmacogenetics for Oral Anticoagulants Metabolism
Current Drug Metabolism Mental Health Patients at High Risk for Obesity, Type 2 Diabetes, and Cardiovascular Disease: An Australian Perspective
Current Hypertension Reviews Nutraceuticals, A New Challenge for Medicinal Chemistry
Current Medicinal Chemistry Calcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk
Current Vascular Pharmacology Cardiac and Metabolic Consequences of Aerobic Exercise Training in Experimental Diabetes
Current Diabetes Reviews Introduction: Advancing Drug Discovery for Alzheimers Disease [ ISOA Fifth Annual Investigators Meeting “Recent Advances in Drug Discovery and Development for Alzheimers Disease” Sponsored by Elan Pharmaceuticals Inc, The Graphic Expression, Glaxo Smith Kline Pharmaceuticals, Neurochem Inc, Pfizer Inc. (Guest Editors: Howard M. Fillit and Lorenzo M. Refolo)]
Current Alzheimer Research Atrial Conduction Disorders
Current Cardiology Reviews Miracles of Herbal Phytomedicines in Treatment of Skin Disorders: Natural Healthcare Perspective
Infectious Disorders - Drug Targets Gender and Cardiovascular Mortality in Northern and Southern European Populations
Current Pharmaceutical Design Targeting Myocardial Metabolism for the Treatment of Stable Angina
Current Pharmaceutical Design Polyphenols: A Nutraceutical Approach Against Diseases
Recent Patents on Food, Nutrition & Agriculture The Assessment of Interleukin-18 on the Risk of Coronary Heart Disease
Medicinal Chemistry L-Arginine Signalling Potential in the Brain: The Peripheral Gets Central
Recent Patents on CNS Drug Discovery (Discontinued) Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets The Metabolic Fate of Apple Polyphenols in Humans
Current Nutrition & Food Science Influence of Leptin on Immunity
Current Immunology Reviews (Discontinued) Coenzyme Q10 and Neurological Diseases: An Update
Letters in Drug Design & Discovery Treatments for Hypertension in Type 2 Diabetes-Non-pharmacological and Pharmacological Measurements<sup>#</sup>
Current Hypertension Reviews